ERBB2 and breast carcinoma: While breast cancer subtypes expressing the estrogen and possibly progesterone receptors (ER/PR) or human epidermal growth factor receptor 2 (HER2) have curative options with targeted adjuvant therapies, the TNBC subtype has limited targeted therapies, and most patients are still mainly treated with chemotherapy44.